CASI PharmaceuticalsFRA:ENM 29 Days Payable is 21.00 as of Dec. 2025, which is 74% below its 10-year median of 79.69. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €11.74. The stock has 5 warning signs investors should review. Among 702 Biotechnology companies, CASI Pharmaceuticals ranks worse than 71.94% on this metric.
The historical rank and industry rank for CASI Pharmaceuticals's Days Payable or its related term are showing as below:
FRA:ENM'
s Days Payable Range Over the Past 10 Years
Min: 43.57 Med: 79.69 Max: 282.03
Current: 43.57
During the past 13 years, CASI Pharmaceuticals's highest Days Payable was 282.03. The lowest was 43.57. And the median was 79.69.
FRA:ENM's Days Payable is ranked worse than 71.94% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs FRA:ENM: 43.57
CASI Pharmaceuticals's Days Payable
increased
from Dec. 2024 (19.76) to Dec. 2025 (21.00).
It may suggest that CASI Pharmaceuticalsdelayed paying its suppliers.
CASI Pharmaceuticals Days Payable Related Terms
CASI Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for CASI Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ENM vs ITRMF, OGEN, AZTR: Days Payable Comparison
For the Biotechnology subindustry, CASI Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CASI Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals (FRA:ENM) has a Days Payable of 21.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CASI Pharmaceuticals and its competitors. This is 74% below median its historical median of 79.69. Over the past decade, CASI Pharmaceuticals' Days Payable has ranged from 43.57 to 282.03. According to the industry distribution chart, CASI Pharmaceuticals ranks #505 out of 702 companies in the Biotechnology industry, placing it in the top 71.9%.
Is CASI Pharmaceuticals' Days Payable too high?
CASI Pharmaceuticals' current Days Payable of 21.00 is 74% below median its 10-year median of 79.69. Over the past 10 years, this metric has ranged from a low of 43.57 to a high of 282.03. The Biotechnology industry median Days Payable is 113.10. CASI Pharmaceuticals' value of 21.00 is 81.4% below this industry median. Based on the distribution chart, CASI Pharmaceuticals ranks #505 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Days Payable compare to ITRMF and OGEN?
According to the Biotechnology industry distribution chart, CASI Pharmaceuticals ranks #505 out of 702 companies for Days Payable. This places CASI Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.10. CASI Pharmaceuticals' value of 21.00 is 81.4% below this benchmark. Historically, CASI Pharmaceuticals' own Days Payable has ranged from 43.57 to 282.03 over the past decade. While the company's 10-year median is 79.69 vs. the industry median of 113.10, CASI Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CASI Pharmaceuticals's current Days Payable of 21.00 is 81.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CASI Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CASI Pharmaceuticals's current Days Payable is 21.00, which is 74% below median its own 10-year median of 79.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current Days Payable of 21.00. The stock's GF Value™ is €11.74, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current Days Payable is 21.00, which is 74% below median its 10-year median of 79.69 and 81.4% below the Biotechnology industry median of 113.10. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Days Payable is 21.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.74.
Key valuation signals for FRA:ENM:
Days Payable: 21.00 (74% below median its 10-year median of 79.69)
GF Value™: €11.74 vs. price of €1.54 (86.9% below fair value)
Industry Position: 81.4% below the Biotechnology median (#505 of 702)
No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for FRA:ENM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ENM has been successfully added to your 
